HERZLIYA, Israel, and CALGARY, Canada — Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA).
Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan’s non-clinical development plan and Phase I clinical study design for the LPT-CBD’s Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA’s Center for Veterinary Medicine (CVM) with the issuance of an Investigational New Animal Drug (INAD) designation in July.
Given recent U.S. Pet industry reports and data released by the American Pet Products Association (APPA) and the National Pet Owners Survey*, Innocan recognizes significant market potential for an injectable treatment for chronic pain in animals:
- 66% of U.S. households – 87 million homes – own one or more pets, including 58 million with dogs and 40 million with cats.
- In 2024, U.S. pet industry expenditures are projected to reach US $156 billion, up from USD $147 billion in 2023, with USD $39 billion anticipated for pharmaceutical drugs and veterinary care.
This new data represents a significantly large and growing market for effective veterinary health products like LPT-CBD, Innocan’s monthly injectable drug product. Innocan’s unique technology is comprised of liposomes loaded with CBD for the treatment of chronic pain. LPT-CBD has demonstrated promising results in multiple animal model tests, as previously reported, providing extended pharmacokinetic benefits and effective pain relief lasting up to four weeks.
Following the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD project, thereby sunsetting its Cannabinoid-Loaded Exosome (CLX) project conducted with Ramot of Tel Aviv University (Ramot) under Prof. Daniel Offen. A suitable notice of termination of its sponsored research agreement dated April 17, 2020 and its research and funding agreement with Ramot dated December 6, 2021 has been sent, concluding this collaboration.
“The latest pet industry reports show that the market potential of the LPT-CBD products in veterinary health is clearly significant,” commented Iris Bincovich, CEO of Innocan. “Our commitment to pioneering solutions for chronic pain in animals aligns with the growing need for effective, compassionate care. By dedicating increased resources to this market, we can expedite our path to market for LPT-CBD and meet the demands of a dynamic and expanding pet care industry.”
About Innocan Pharma
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle.